STOCKHOLM, Sweden, Feb. 23, 2004 (PRIMEZONE) -- Patients with chronic injuries to the ulnar collateral ligament (UCL) in the first metacarpophalangeal joint (thumb ligament) show that the initially good results with stable joints remain 2 years after surgery.
In chronic injuries to the ulnar collateral ligament (UCL) in the first metacarpophalangeal joint, a free tendon graft is recommended. However, many surgeons prefer MP joint fusion due to elongation of the tendon graft.
Artimplant has together with hand surgeons at Sahlgrenska University Hospital developed an Augmentation device for repair of chronic ulnar collateral ligament injuries. The device is made from ArtelonTM and will act as a reinforcement to the autograft.
Five patients with chronic UCL instability have been included in a pilot study and followed-up for 2 years.
For additional information, please contact: Tord Lendau, CEO phone +46 (0)708 369 403 tord.lendau@artimplant.se
ARTIMPLANT
Artimplant is a biomaterial company that focuses on orthopedic surgery solutions. The company runs R&D operations for biodegradable implants and develops manufacturing processes for the implants. Its goal is to enable active lives. Artimplant's biomaterial is based on a new technology that's opening new markets within orthopedic surgery and closely related areas that have extensive med-tech needs.
Artimplant developed and patented several different degradable ligament implants that are now in clinical trials. The company's business concept is to license products and technologies to global partners.
The Artimplant share is listed on the Stockholm stock exchange's O list.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/02/23/20040223BIT00530/wkr0001.doc
http://www.waymaker.net/bitonline/2004/02/23/20040223BIT00530/wkr0002.pdf